Rigel Pharmaceuticals, Inc.

NasdaqGS:RIGL Rapport sur les actions

Capitalisation boursière : US$458.7m

Rigel Pharmaceuticals Gestion

Gestion contrôle des critères 3/4

Le PDG Rigel Pharmaceuticals est Raul Rodriguez, nommé en May2010, a un mandat de 14.5 ans. La rémunération annuelle totale est $ 3.44M, composée du salaire de 21.2% et des bonus 78.8%, y compris les actions et options de la société. détient directement 0.74% des actions de la société, d'une valeur de $ 3.42M. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 3.5 ans et 6.3 ans.

Informations clés

Raul Rodriguez

Directeur général

US$3.4m

Rémunération totale

Pourcentage du salaire du PDG21.2%
Durée du mandat du directeur général14.5yrs
Propriété du PDG0.7%
Durée moyenne d'occupation des postes de direction3.5yrs
Durée moyenne du mandat des membres du conseil d'administration6.3yrs

Mises à jour récentes de la gestion

Recent updates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Nov 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Could Be 36% Below Their Intrinsic Value Estimate

Rigel Pharma Remains Bullish, Growth Fueled By FDA-Approved Drugs, Strategic Partnerships

Oct 10

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

Sep 25
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Shares Fly 31% But Investors Aren't Buying For Growth

There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Jul 30
There's No Escaping Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Muted Revenues Despite A 29% Share Price Rise

Rigel Pharmaceuticals: Undervalued FDA-Approved Products With Promising Cash Flow Potential

Jul 24

Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

May 01
Little Excitement Around Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Revenues As Shares Take 29% Pounding

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Mar 08
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Reported Earnings Last Week And Analysts Are Already Upgrading Their Estimates

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Mar 04
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Surges 36% Yet Its Low P/S Is No Reason For Excitement

Rigel Pharmaceuticals: Upgrading To A 'Top Idea' Ahead Of Promising Q4/2023 Earnings Report

Feb 23

Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Jan 15
Lacklustre Performance Is Driving Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) Low P/S

Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Oct 25
Is Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Trading At A 25% Discount?

Rigel cutting 16% of workforce after declining to file sNDA for fostamatinib

Oct 10

Rigel Pharma adds ~7% to reach over two month high

Aug 18

Rigel rises 17% on strong Q2 result

Aug 03

Rigel Pharmaceuticals: A Status Check

May 31

Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Apr 21
Is Rigel Pharmaceuticals (NASDAQ:RIGL) A Risky Investment?

Rigel Pharmaceuticals: Why The Stock Is On A Run

Mar 21

Analyse de la rémunération des PDG

Comment la rémunération de Raul Rodriguez a-t-elle évolué par rapport aux bénéfices de Rigel Pharmaceuticals?
DateRémunération totaleSalaireBénéfices de l'entreprise
Sep 30 2024n/an/a

US$4m

Jun 30 2024n/an/a

-US$14m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$3mUS$728k

-US$25m

Sep 30 2023n/an/a

-US$24m

Jun 30 2023n/an/a

-US$38m

Mar 31 2023n/an/a

-US$45m

Dec 31 2022US$3mUS$700k

-US$59m

Sep 30 2022n/an/a

-US$83m

Jun 30 2022n/an/a

-US$85m

Mar 31 2022n/an/a

-US$85m

Dec 31 2021US$3mUS$662k

-US$18m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$3mUS$662k

-US$30m

Sep 30 2020n/an/a

-US$28m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$28m

Dec 31 2019US$3mUS$649k

-US$67m

Sep 30 2019n/an/a

-US$46m

Jun 30 2019n/an/a

-US$59m

Mar 31 2019n/an/a

-US$64m

Dec 31 2018US$4mUS$637k

-US$70m

Sep 30 2018n/an/a

-US$100m

Jun 30 2018n/an/a

-US$93m

Mar 31 2018n/an/a

-US$87m

Dec 31 2017US$2mUS$618k

-US$78m

Rémunération vs marché: La rémunération totale de Raul ($USD 3.44M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.14M ).

Rémunération et revenus: La rémunération de Raul a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Raul Rodriguez (63 yo)

14.5yrs

Titularisation

US$3,440,790

Compensation

Mr. Raul R. Rodriguez has been the Chief Executive Officer and Director of Rigel Pharmaceuticals, Inc., since November 2014 and its President since May 2010. Mr. Rodriguez served as Chief Operating Officer...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Raul Rodriguez
President14.5yrsUS$3.44m0.74%
$ 3.4m
Dean Schorno
Executive VP & CFO6.5yrsUS$1.21m0.069%
$ 316.7k
Raymond Furey
Executive VP1.9yrsUS$683.00k0.0028%
$ 13.0k
David Santos
Executive VP & Chief Commercial Officer4.3yrsUS$1.34m0.031%
$ 143.4k
Julie Patel
Senior VP of Human Resources2.8yrspas de donnéespas de données
Esteban Masuda
Executive Vice President of Research8.2yrsUS$796.09kpas de données
Joseph Lasaga
Executive VP & Chief Business Officerless than a yearpas de donnéespas de données
Lisa Rojkjaer
Executive VP & Chief Medical Officerless than a yearpas de donnéespas de données
Tarek Sallam
Vice President of Marketingno datapas de donnéespas de données

3.5yrs

Durée moyenne de l'emploi

61yo

Âge moyen

Gestion expérimentée: L'équipe de direction de RIGL est considérée comme expérimentée (ancienneté moyenne 3.5 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Raul Rodriguez
President10yrsUS$3.44m0.74%
$ 3.4m
Walter Moos
Independent Director27.7yrsUS$138.58k0.044%
$ 201.1k
Jane Wasman
Independent Director5.7yrsUS$145.58k0.043%
$ 195.3k
Gregory Lapointe
Independent Chairman of the Board7yrsUS$190.58k0.043%
$ 195.3k
Kamil Jackson
Independent Director2.9yrsUS$140.58k0.025%
$ 113.9k
Alison Hannah
Independent Director3.5yrsUS$212.98k0.032%
$ 146.5k

6.3yrs

Durée moyenne de l'emploi

65yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de RIGL sont considérés comme expérimentés (ancienneté moyenne 6.3 ans).